Humacyte presented the 36‑month safety and efficacy data for its Symvess acellular tissue‑engineered vessel at the Vascular & Endovascular Surgery Society (VESS) Annual Winter Meeting in Olympic Valley, CA, on February 18, 2026. The presentation, titled “Long‑Term Outcomes of the Acellular Tissue Engineered Vessel in Extremity Arterial Trauma Repair: Results from the V005 Trial,” highlighted outcomes from 54 patients who received Symvess when autologous vein was not feasible.
The data show a 92.9% infection‑free rate from months 3 to 36, with only three conduit infections overall. Limb‑salvage rates were 87.3% at 12 months and 82.5% at 24 months. Duplex ultrasound demonstrated that the graft’s mid‑vessel diameter remained stable, with no evidence of dilatation or narrowing over the 36‑month period.
These results reinforce Symvess’s clinical profile and are particularly meaningful because the product received full FDA approval on December 19, 2024, and entered commercial launch on February 26, 2025. The 36‑month data were previously published in the Journal of Vascular Surgery Cases, Innovations and Techniques on December 22, 2025, and the VESS presentation serves as a public dissemination of that evidence. The data also support ongoing discussions with hospitals and payers about reimbursement and adoption, and they align with recent U.S. Department of Defense procurement interest announced on February 9, 2026.
Dr. Curi, a senior investigator in the V005 study, noted, “These long‑term results demonstrate the potential of Symvess to meet the needs of trauma patients when autologous vein is not available or feasible. During the V005 study, there were sustained low rates of infection, no conduit related deaths, and excellent Symvess durability out to three years—outcomes that translate into meaningful benefits for patients facing life or limb‑threatening injuries where autologous reconstruction is not an option.”
The presentation underscores Humacyte’s strategy to position Symvess as a reliable off‑the‑shelf alternative to autologous vein in trauma settings. By providing robust long‑term data, the company strengthens its case for reimbursement, facilitates broader adoption, and supports its competitive positioning against conventional graft options.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.